Although anti-VEGF agents can markedly improve the clinical outcome of wet AMD, they have been unable to induce complete angiogenesis regression, and only 30–40% of individuals experienced vision improvement after treatment (Folk and Stone, 2010; Krüger Falk et al., 2013). This evidence concerns the gene VEGFA and wet macular degeneration.